Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 25;106(4):1763–1774. doi: 10.1210/clinem/dgaa958

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — VP1 assessment in GD samples and controls. We confirmed the presence of VP1 in GD samples. A, Number of VP1⁺ thyrocytes in the GD subgroups and controls. There were significantly more VP1⁺ thyrocytes both in the chronic GD group and the new GD group compared to controls. The chronic GD group had significantly more VP1⁺ thyrocytes than the new GD group. Bars represent median and interquartile range. B, Proportion of double-positive samples (VP1⁺/HLA I⁺) in the GD group and the controls. We found significantly more double-positive samples in the GD group than in the control group. *P less than or equal to .05; **P less than or equal to .01; ***P less than or equal to .001. GD, Graves disease; HLA, human leukocyte antigen; VP1, enteroviral capsid protein 1.